胃部・食道胃接合部腺癌市場:ヨーロッパ主要国の治療薬市場

◆英語タイトル:Gastric and Gastroesophageal Junction Adenocarcinoma - 5EU Drug Forecast and Market Analysis to 2024
◆商品コード:GDHC291CFR
◆発行会社(調査会社):GlobalData
◆発行日:2015年12月9日
◆ページ数:283
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:ヨーロッパ
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD6,995 ⇒換算¥797,430見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD13,990 ⇒換算¥1,594,860見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD20,985 ⇒換算¥2,392,290見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Gastric and Gastroesophageal Junction Adenocarcinoma – 5EU Drug Forecast and Market Analysis to 2024
Summary

Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer death in the world. The major treatments for G/GEJAC are chemotherapy-based, but targeted therapies such as HER2 and angiogenesis inhibitors have been approved and are being added to chemotherapy regimens since 2010 and 2014, respectively.

GlobalData expects that the cost consciousness of the 5EU healthcare systems, as well as the difficulties in getting reimbursement approval in individual 5EU countries, will limit the growth of the G/GEJAC market. For example, the high price of Cyramza in the US relative to Herceptin received criticism from interviewed EU KOLs. GlobalData expects that, if Eli Lilly imposes the same pricing strategy for Cyramza in the 5EU, it will have difficulty obtaining reimbursement approval. This kind of reimbursement requirement will slow down the growth of the 5EU G/GEJAC market.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Overview of G/GEJAC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU G/GEJAC market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for G/GEJAC.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2014-2024 in 5EU

【レポートの目次】

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Biomarkers/Targets of Interest
3.2 Staging
3.3 Symptoms
3.4 Prognosis
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Screening
4.1.2 Diagnosis
4.1.3 Treatment Guidelines and Leading Prescribed Drugs
4.1.4 Clinical Practice
4.2 France
4.2.1 Screening and Diagnosis
4.2.2 Clinical Practice
4.3 Germany
4.3.1 Screening and Diagnosis
4.3.2 Clinical Practice
4.4 Italy
4.4.1 Screening and Diagnosis
4.4.2 Clinical Practice
4.5 Spain
4.5.1 Screening and Diagnosis
4.5.2 Clinical Practice
4.6 UK
4.6.1 Screening and Diagnosis
4.6.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 HER2-Targeted Therapy
5.2.1 Herceptin (trastuzumab)
5.3 Angiogenesis Inhibitors
5.3.1 Cyramza (ramucirumab)
5.3.2 Aitan (apatinib)
5.4 Chemotherapies
5.4.1 TS-1 (tegafur, gimeracil, oteracil)
5.4.2 Abraxane (nab-paclitaxel)
6 Unmet Need and Opportunity
6.1 Overview
6.2 First-Line Therapy for HER2-Negative Patients
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 New Molecular Targets for Targeted Therapies
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Effective Perioperative and Postoperative Therapies
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 More Efficacious HER2-Targeted Therapies
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Peritoneal Metastases
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Better Clinical Trial Design
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
6.8 Early Detection of Gastric and Gastroesophageal Adenocarcinomas
6.8.1 Unmet Need
6.8.2 Gap Analysis
6.8.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Phase III Clinical Development
7.3 HER2-Targeted Therapies
7.3.1 Kadcyla (T-DM1; trastuzumab emtansine)
7.3.2 Perjeta (pertuzumab)
7.4 Immune Checkpoint Inhibitors
7.4.1 Keytruda (pembrolizumab)
7.4.2 Opdivo (nivolumab)
7.5 Further Strategies for G/GEJAC Treatment
7.5.1 Napabucasin
7.5.2 Lynparza (olaparib)
7.5.3 Nimotuzumab
7.5.4 TAS-118
7.6 Early/Near-Phase III Pipeline Drugs
7.6.1 GS-5745
7.6.2 Masitinib
7.7 Promising Drugs in Early-Stage Development
7.7.1 Immune Checkpoint Inhibitors
7.7.2 MET-Targeting Drugs
7.7.3 Antibody-Drug Conjugates
7.8 Biosimilars
8 Market Outlook
8.1 5EU
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers – France
8.1.4 Drivers and Barriers – Germany
8.1.5 Drivers and Barriers – Italy
8.1.6 Drivers and Barriers – Spain
8.1.7 Drivers and Barriers – UK
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed G/GEJAC Patients
9.4.2 Percent of Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline Agents
9.5 Primary Research – Key Opinion Leaders Interviewed for this Report
9.6 Primary Research – High-Prescriber Survey
9.7 About the Authors
9.8 About GlobalData
9.9 Disclaimer

1.1 List of Tables
Table 1: Stage Definitions for Gastric Cancer
Table 2: Symptoms of Gastric Cancer
Table 3: Prognosis of Gastric Cancer in the US and UK
Table 4: Clinical Guidelines for Gastric Cancer
Table 5: Generic Chemotherapy Regimens Indicated for Gastric Cancer
Table 6: Country Profile - France
Table 7: Country Profile - Germany
Table 8: Country Profile - Italy
Table 9: Country Profile - Spain
Table 10: Country Profile - UK
Table 11: Leading Treatments for G/GEJAC, 2015
Table 12: Product Profile - Herceptin
Table 13: Summary of Results from the ToGA Trial of Herceptin plus FC
Table 14: Summary of the Results of the Analysis of the HER2 IHC3+ or IHC2+/FISH+ Subgroup
Table 15: Summary of AEs from the ToGA Trial of Herceptin plus FC
Table 16: Herceptin SWOT Analysis, 2015
Table 17: Global Sales Forecasts ($m) for Herceptin, 2014-2024
Table 18: Product Profile - Cyramza
Table 19: Summary of the Results from the REGARD of Cyramza
Table 20: Summary of the Results from the RAINBOW Trial of Cyramza plus Paclitaxel
Table 21: Summary of Trial Results of Cyramza in Combination with mFOLFOX6 in the First-Line Setting
Table 22: Summary of AEs from the REGARD Trial of Cyramza Monotherapy
Table 23: Summary of AEs from the RAINBOW Trial of Cyramza plus Paclitaxel
Table 24: Cyramza SWOT Analysis, 2015
Table 25: Global Sales Forecasts ($m) for Cyramza, 2014-2024
Table 26: Product Profile - Aitan
Table 27: Summary of Aitan Trial Results
Table 28: Summary of AEs from Phase III Trial of Aitan
Table 29: Aitan SWOT Analysis, 2015
Table 30: Global Sales Forecasts ($m) for Aitan, 2014-2024
Table 31: Product Profile - TS-1
Table 32: Summary of the Results of Three Studies of TS-1 Monotherapy
Table 33: Summary of the Results from the ACTS-GC Study of TS-1
Table 34: Summary of TS-1 in the DIGEST trial
Table 35: Summary of AEs from ACTS=GS Trial of TS-1 Adjuvant Treatment
Table 36: Summary of AEs from Trial of TS-1 plus Cisplatin
Table 37: TS-1 SWOT Analysis, 2015
Table 38: Global Sales Forecasts ($m) for TS-1, 2014-2024
Table 39: Product Profile - Abraxane
Table 40: Summary of Results from a Phase II Trial of Abraxane
Table 41: Safety of Abraxane
Table 42: Abraxane SWOT Analysis, 2015
Table 43: Global Sales Forecasts ($m) for Abraxane, 2014-2024
Table 44: Unmet Needs and Opportunities in G/GEJAC
Table 45: Product Profile - Kadcyla
Table 46: Kadcyla SWOT Analysis, 2015
Table 47: Product Profile - Perjeta
Table 48: Summary of the Results of the Phase IIa Trial of the Herceptin/Perjeta-CX Combination
Table 49: Safety of the Herceptin/Perjeta-CX Combination
Table 50: Perjeta SWOT Analysis, 2015
Table 51: Global Sales Forecasts ($m) for Perjeta, 2014-2024
Table 52: Product Profile - Keytruda
Table 53: Summary of the Results of the KEYNOTE-012 Trial of Keytruda
Table 54: Keytruda SWOT Analysis, 2015
Table 55: Global Sales Forecasts ($m) for Keytruda, 2014-2024
Table 56: Product Profile - Opdivo
Table 57: Opdivo SWOT Analysis, 2015
Table 58: Global Sales Forecasts ($m) for Opdivo, 2014-2024
Table 59: Product Profile - Napabucasin
Table 60: Summary of the Results from the Phase Ib/II Trial of Napabucasin
Table 61: Napabucasin SWOT Analysis, 2015
Table 62: Global Sales Forecasts ($m) for Napabucasin, 2014-2024
Table 63: Product Profile - Lynparza
Table 64: Summary of Results of the Phase II Trial of Lynparza
Table 65: Summary of AEs from Phase II Trial of Lynparza
Table 66: Lynparza SWOT Analysis, 2015
Table 67: Global Sales Forecasts ($m) for Lynparza, 2014-2024
Table 68: Product Profile - Nimotuzumab
Table 69: Summary of the Results of the Phase II Trial of Nimotuzumab in Unselected Patients
Table 70: Summary of the Results of the Subgroup Analysis of Nimotuzumab in EGFR-Positive Patients
Table 71: Summary of AEs from the Phase II Trial of Nimotuzumab in Combination with Irinotecan
Table 72: Nimotuzumab SWOT Analysis, 2015
Table 73: Global Sales Forecasts ($m) for nimotuzumab, 2014-2024
Table 74: Product Profile - TAS-118
Table 75: TAS-118 SWOT Analysis, 2015
Table 76: Global Sales Forecasts ($m) for TAS-118, 2014-2024
Table 77: Product Profile - GS-5745
Table 78: GS-5745 SWOT Analysis
Table 79: Product Profile - Masitinib
Table 80: Summary of the Results of the Phase II Trial of the Masitinib-Chemotherapy Combinations
Table 81: Summary of AEs from the Phase II Trial of the Masitinib-Chemotherapy Combinations
Table 82: Masitinib SWOT Analysis, 2013
Table 83: Early-Stage Immune Checkpoint Inhibitors
Table 84: Early-Stage MET-Targeting Drugs
Table 85: Early-Stage Antibody-Drug-Conjugates
Table 86: Marketed or Phase III Trastuzumab Biosimilars
Table 87: Sales Forecast ($m) for G/GEJAC in the 5EU, 2014-2024
Table 88: Key Events Impacting Sales for G/GEJAC in the 5EU, 2014-2024
Table 89: G/GEJAC Market in France - Drivers and Barriers, 2015
Table 90: G/GEJAC Market in Germany - Drivers and Barriers, 2015
Table 91: G/GEJAC Market in Italy - Drivers and Barriers, 2015
Table 92: G/GEJAC Market in Spain - Drivers and Barriers, 2015
Table 93: G/GEJAC Market in the UK - Drivers and Barriers, 2015
Table 94: Key Launch Dates
Table 95: Key Patent Expiries
Table 96 Average Body Weight and Surface Area Across the 8MM
Table 97: Average Cost of Therapy of Herceptin
Table 98: Average Cost of Therapy of Cyramza
Table 99: Average Cost of Therapy of TS-1
Table 100: Average Cost of Therapy of Abraxane
Table 101: High-Prescribing Physicians Surveyed by Country

1.2 List of Figures
Figure 1: Treatment Flowchart for Localized Gastric Cancer
Figure 2: Treatment Flowchart for Locoregional Gastric cancer
Figure 3: Treatment Flowchart for Metastatic Gastric Cancer
Figure 4: Herceptin’s Development in G/GEJAC
Figure 5: Development of Cyramza in G/GEJAC
Figure 6: Development of TS-1 in G/GEJAC
Figure 7: Development of Abraxane in Gastric Cancer
Figure 8: G/GEJAC - Phase III Pipeline, 2015
Figure 9: Competitive Assessment of Late-Stage Pipeline Agents in G/GEJAC, 2014-2024
Figure 10: Kadcyla’s Development in G/GEJAC
Figure 11: Clinical and Commercial Positioning of Kadcyla
Figure 12: Perjeta’s Development in G/GEJAC
Figure 13: Clinical and Commercial Positioning of Perjeta
Figure 14: Keytruda’s Development in G/GEJAC
Figure 15: Clinical and Commercial Positioning of Keytruda
Figure 16: Opdivo’s Development in G/GEJAC
Figure 17: Clinical and Commercial Positioning of Opdivo
Figure 18: Napabucasin ’s Development in G/GEJAC
Figure 19: Clinical and Commercial Positioning of Napabucasin
Figure 20: Lynparza’s Development in G/GEJAC
Figure 21: Clinical and Commercial Positioning of Lynparza
Figure 22: Nimotuzumab’s Development in Gastric Cancer
Figure 23: Clinical and Commercial Positioning of Nimotuzumab
Figure 24: TAS-118’s Development in Gastric Cancer
Figure 25: Clinical and Commercial Positioning of TAS-118
Figure 26: GS-5745 ’s Development in G/GEJAC
Figure 27: Clinical and Commercial Positioning of GS-5745
Figure 28: Clinical and Commercial Positioning of masitinib
Figure 29: Sales for G/GEJAC in the 5EU by Drug Class, 2014-2024

★調査レポート[胃部・食道胃接合部腺癌市場:ヨーロッパ主要国の治療薬市場]販売に関する免責事項
★調査レポート[胃部・食道胃接合部腺癌市場:ヨーロッパ主要国の治療薬市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆